- Home
- ALXO vs BRLT Comparison
ALXO vs BRLT Comparison
Compare ALXO & BRLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- BRLT
- Stock Information
- Founded
- ALXO 2015
- BRLT 2005
- Country
- ALXO United States
- BRLT United States
- Employees
- ALXO N/A
- BRLT N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- BRLT Consumer Specialties
- Sector
- ALXO Health Care
- BRLT Consumer Discretionary
- Exchange
- ALXO Nasdaq
- BRLT Nasdaq
- Market Cap
- ALXO 24.0M
- BRLT 21.8M
- IPO Year
- ALXO 2020
- BRLT 2021
- Fundamental
- Price
- ALXO $0.41
- BRLT $1.38
- Analyst Decision
- ALXO Strong Buy
- BRLT Hold
- Analyst Count
- ALXO 6
- BRLT 3
- Target Price
- ALXO $3.30
- BRLT $1.80
- AVG Volume (30 Days)
- ALXO 613.7K
- BRLT 54.4K
- Earning Date
- ALXO 08-07-2025
- BRLT 08-07-2025
- Dividend Yield
- ALXO N/A
- BRLT N/A
- EPS Growth
- ALXO N/A
- BRLT N/A
- EPS
- ALXO N/A
- BRLT N/A
- Revenue
- ALXO N/A
- BRLT $418,708,000.00
- Revenue This Year
- ALXO N/A
- BRLT $3.79
- Revenue Next Year
- ALXO N/A
- BRLT $3.85
- P/E Ratio
- ALXO N/A
- BRLT N/A
- Revenue Growth
- ALXO N/A
- BRLT N/A
- 52 Week Low
- ALXO $0.40
- BRLT $1.25
- 52 Week High
- ALXO $8.78
- BRLT $2.68
- Technical
- Relative Strength Index (RSI)
- ALXO 40.22
- BRLT 49.19
- Support Level
- ALXO $0.45
- BRLT $1.32
- Resistance Level
- ALXO $0.53
- BRLT $1.40
- Average True Range (ATR)
- ALXO 0.05
- BRLT 0.05
- MACD
- ALXO -0.01
- BRLT 0.00
- Stochastic Oscillator
- ALXO 4.98
- BRLT 50.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.